Physician profile
Delayna Hunter
NPI 1639591506
$1,398.74
in general payments reported to CMS, 2019-2025
15 companies · $324 in 2025
The $324 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $259 · 2022: $59.26 · 2023: $386 · 2024: $371 · 2025: $324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,080.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,080.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $461.86 | 2021-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $357.52 | 2021-2025 | Jardiance, Mounjaro, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.47 | 2021-2024 | Tradjenta, Synjardy, Jardiance |
| Amgen INC. | $88.13 | 2021-2025 | Otezla, Repatha, Repatha |
| Sumitomo Pharma America, INC. | $85.20 | 2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $63.62 | 2023 | |
| Glaxosmithkline, LLC. | $42.19 | 2021-2023 | Shingrix |
| Viatris Specialty LLC | $38.01 | 2025 | Yupelri |
| Amarin Pharma, INC. | $35.26 | 2021 | |
| Merck Sharp & Dohme LLC | $26.86 | 2021-2025 | Capvaxive, Rotateq, Vaxneuvance |
| Abbvie INC. | $18.53 | 2021 | |
| Sunovion Pharmaceuticals INC. | $18.33 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $17.05 | 2025 | Breztri |
| Grifols USA, LLC | $14.01 | 2024 | Prolastin-C Liquid |
| Roche Diagnostics Corporation | $11.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Delayna Hunter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.